The Role of Prostate-Specific Antigen in Prostate Cancer Screening

Open access

Abstract

Prostate cancer is, after lung cancer, the most common malignant disease diagnosed in the male population. The introduction into the practice used during the 80’s and 90’s of the determination of serum Prostate-Specific Antigen (PSA) levels, as a component of screening for prostate cancer, was a turning point in the medical practice. Due to this enzyme produced exclusively by the prostate gland, the prostate cancer detection rate (in curative, intracapsular stages) improved significantly. Serum PSA is a better predictive factor for prostate cancer (PC) than digital rectal examination or transrectal prostatic ultrasound.

1. Gretzer MB, Partin AW. Chapter 93. Prostate cancer tumor markers. In: Wein AJ, ed. Campbell-Walsh Urology. 9th ed. Philadelphia, PA: Saunders; 2007;2896-906.

2. Watt KW, Lee PJ, M’Timkulu T, Chan WP, Loor R. Human prostate-specific antigen: structural and functional similarity with serine proteases. Proc Natl Acad Sci U S A. 1986 May;83(10):3166-70. DOI: 10.1073/ pnas.83.10.3166

3. Lilja H, Laurell CB. The predominant protein in human seminal coagulate. Scand J Clin Lab Invest. 1985 Nov;45(7):635-41. DOI: 10.3109/00365518509155271

4. Wang MC, Valenzuela LA, Murphy GP, Chu TM. Purification of a human prostate specific antigen. Invest Urol. 1979 Sep;17(2):159-63.

5. Kuriyama M, Wang MC, Papsidero LD, Killian CS, Shimano T, Valenzuela L, et al. Quantitation of prostate specific antigen in serum by a sensitive enzyme immunoassay. Cancer Res. 1980 Dec;40(12):4658-62.

6. Kuriyama M, Wang MC, Lee CI, Papsidero LD, Killian CS, Inaji H, et al. Use of human prostate-specific antigen in monitoring prostate cancer. Cancer Res. 1981 Oct;41(10):3874-6.

7. Seamonds B. Reference intervals for prostate-specific antigen. Clin Chem. 1988 Jun;34(6):1366-7.

8. Stamey TA, Yang N, Hay AR, McNeal JE, Freiha FS, Redwine E. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med. 1987 Oct 8;317(15):909-16. DOI: 10.1056/ NEJM198710083171501

9. Oesterling JE, Chan DW, Epstein JI, Kimball AW Jr, Bruzek DJ, Rock RC, et al. Prostate specific antigen in the preoperative and postoperative evaluation of localized prostatic cancer treated with radical prostatectomy. J Urol. 1988 Apr;139(4):766-72.

10. Lilja H, Christensson A, Dahlén U, Matikainen MT, Nilsson O, Pettersson K, et al. Prostate-specific antigen in serum occurs predominantly in complex with alpha 1-antichymotrypsin. Clin Chem. 1991 Sep;37(9):1618-25.

11. Ambert V. Diagnosticul in cancerul de prostata, Bucuresti, Editura Universitara Carol Davila, Bucuresti. 2011;74-93.

12. Christensson A, Björk T, Nilsson O, Dahlén U, Matikainen MT, Cockett AT, et al. Serum prostate specific antigen complexed to alpha 1-antichymotrypsin as an indicator of prostate cancer. J Urol. 1993 Jul;150(1):100-5.

13. Catalona WJ, Richie JP, Ahmann FR, Hudson MA, Scardino PT, Flanigan RC, et al. Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men. J Urol. 1994 May;151(5):1283-90.

14. Stanciu AE. Clinical applications of total PSA and free PSA tumor markers. Rev Romana Med Lab. 2005;1(1):33-7.

15. Dema A, Taban SM, Lazar E, Anderco D, Loghin A, Lazureanu C, et al. Alpha-methylacyl-CoA-racemase expression in variants and unusual patterns of prostate carcinoma. Rev Romana Med Lab. 2011;19(4):319-31.

16. Thompson IM, Pauler DK, Goodman PJ, Tangen CM, Lucia MS, Parnes HL, Minasian LM, Ford LG, Lippman SM, Crawford ED, Crowley JJ, Coltman CA Jr. Prevalence ofprostate cancer among men with a prostate- specific antigen level < or =4.0 ng per milliliter. N Engl J Med. 2004 May 27;350(22):2239-46. DOI: 10.1056/NEJMoa031918

17. Gilbert SM, Cavallo CB, Kahane H, Lowe FC. Evidence suggesting PSA cutpoint of 2.5 ng/mL for prompting prostate biopsy: review of 36,316 biopsies. Urology. 2005 Mar;65(3):549-53. DOI: 10.1016/j.urology. 2004.10.064

18. Börgermann C, Loertzer H, Hammerer P, Fornara P, Graefen M, Rübben H. Problems, objective, and substance of early detection of prostate cancer. Urologe A. 2010 Feb;49(2):181-9. DOI: 10.1007/s00120-010-2234-7

19. www.auanet.org/education/guidelines/prostate-cancer- detection.cfm

20. Schaeffer EM, Carter HB, Kettermann A, Loeb S, Ferrucci L, Landis P, et al. Prostate specific antigen testing among the elderly--when to stop? J Urol. 2009 Apr;181(4):1606-14; discussion 1613-4. DOI: 10.1016/j.juro.2008.11.117

21. Stamey TA, Yang N, Hay AR, McNeal JE, Freiha FS, Redwine E. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med. 1987 Oct 8;317(15):909-16. DOI: 10.1056/ NEJM198710083171501

22. Herschman JD, Smith DS, Catalona WJ. Effect of ejaculation on serum total and free prostate-specific antigen concentrations. Urology. 1997 Aug;50(2):239-43. DOI: 10.1016/S0090-4295(97)00209-4

23. Carter HB, Pearson JD, Metter EJ, Brant LJ, Chan DW, Andres R, Fozard JL,Walsh PC. Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease. JAMA. 1992 Apr 22-29;267(16):2215-20. DOI: 10.1001/ jama.1992.03480160073037

24. Sinescu I, Chibelean C, Cerempei V, Dudu C, Iordache A, Voinea S, et al. Cancerul de prostată. In Sinescu I, Gluck G. Tratat de Urologie, 1st edition, 3rd volume, Editura Medicala, Bucuresti. 2008;2376-8.

25. Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, Mason MD, et al. In Guidelines on Prostate Cancer, European Association of Urology Guidelines, Drukkerij Gelderland, Arnhem. 2013;16-17.

26. Stamey TA, Kabalin JN, McNeal JE, Johnstone IM, Freiha F, Redwine EA, et al. Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. II. Radical prostatectomy treated patients. J Urol. 1989 May;141(5):1076-83.

27. Catalona WJ, Richie JP, deKernion JB, Ahmann FR, Ratliff TL, Dalkin BL, et al. Comparison of prostate specific antigen concentration versus prostate specific antigen density in the early detection of prostate cancer: receiver operating characteristic curves. J Urol. 1994 Dec;152(6 Pt 1):2031-6.

28. Stephan C, Stroebel G, Heinau M, Lenz A, Roemer A, Lein M, et al. The ratio of prostate-specific antigen (PSA) to prostate volume (PSA density) as a parameter to improve the detection of prostate carcinoma in PSA values in the range of < 4 ng/mL. Cancer. 2005 Sep 1;104(5):993-1003. DOI: 10.1002/cncr.21267

29. Catalona WJ, Partin AW, Slawin KM, Brawer MK, Flanigan RC, Patel A, et al. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. JAMA. 1998 May 20;279(19):1542-7. DOI: 10.1001/jama.279.19.1542

30. Djavan B, Zlotta A, Kratzik C, Remzi M, Seitz C, Schulman CC, et al. PSA, PSA density, PSA density of transition zone, free/total PSA ratio, and PSA velocity for early detection of prostate cancer in men with serum PSA 2.5 to 4.0 ng/mL. Urology. 1999 Sep;54(3):517-22. DOI: 10.1016/S0090-4295(99)00153-3

31. Stephan C, Lein M, Jung K, Schnorr D, Loening SA. The influence of prostate volume on the ratio of free to total prostate specific antigen in serum of patients with prostate carcinoma and benign prostate hyperplasia. Cancer. 1997 Jan 1;79(1):104-9. DOI: 10.1002/(SICI) 1097-0142(19970101)79:1<104::AID-CNCR15>3.0. CO;2-8

32. Oesterling JE, Jacobsen SJ, Chute CG, Guess HA, Girman CJ, Panser LA, et al. Serum prostate-specific antigen in a community-based population of healthy men. Establishment of age-specific reference ranges. JAMA. 1993 Aug 18;270(7):860-4. DOI: 10.1001/ jama.1993.03510070082041

33. Catalona WJ, Hudson MA, Scardino PT, Richie JP, Ahmann FR, Flanigan RC, et al. Selection of optimalprostate specific antigen cutoffs for early detection of prostate cancer: receiver operating characteristic curves. J Urol. 1994 Dec;152(6 Pt 1):2037-42.

34. Auprich M, Bjartell A, Chun FK, de la Taille A, Freedland SJ, Haese A, et al. Contemporary role of prostate cancer antigen 3 in the management of prostate cancer. Eur Urol. 2011 Nov;60(5):1045-54. DOI: 10.1016/j. eururo.2011.08.003

35. Sapre N, Selth LA. Circulating MicroRNAs as Biomarkers of Prostate Cancer: The State of Play. Prostate Cancer. 2013 Mar 12;2013:e539680. DOI: 10.1155/2013/539680

36. Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, Mason MD, et al. In Guidelines on Prostate Cancer, European Association of Urology Guidelines, Drukkerij Gelderland, Arnhem. 2013;14-15.

37. Wilt TJ, Ahmed HU. Prostate cancer screening and the management of clinically localized disease. BMJ. 2013 Jan;346:f325. DOI: 10.1136/bmj.f325

Revista Romana de Medicina de Laborator

Romanian Journal of Laboratory Medicine

Journal Information


IMPACT FACTOR 2017: 0.400
5-year IMPACT FACTOR: 0.320



CiteScore 2017: 0.31

SCImago Journal Rank (SJR) 2017: 0.144
Source Normalized Impact per Paper (SNIP) 2017: 0.195

Metrics

All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 127 127 41
PDF Downloads 65 65 28